Key Takeaways

  • BPCR repurchased 150,000 ordinary shares on 26 May 2026 at a flat price of $0.95 per share.
  • Investec Bank plc acted as the executing broker, with all activity carried out on the LSE trading venue.
  • Shares were taken into treasury, which now stands at 251,739,289 ordinary shares.
  • Ordinary shares in issue (excluding treasury) and total voting rights both stand at 1,122,192,778.
  • The RNS announcement was released at 18:15 on 26 May 2026 under RNS Number 7725F.

Introduction

BioPharma Credit PLC (LSE:BPCR), the London-listed specialist Debt investor in the life sciences industry, has provided a fresh update on its own-share activity. In a Regulatory News Service (RNS) announcement released through the London Stock Exchange on 26 May 2026 at 18:15, BPCR confirmed it had purchased 150,000 of its ordinary shares of US $0.01 each on the same trading day. The transaction was executed by Investec Bank plc on the LSE at a flat price of $0.95 per share, and the shares have been taken into treasury rather than cancelled. For investors tracking specialist UK Investment trusts and life sciences debt vehicles, the announcement provides a small but precise data point on how BPCR is managing its share count and Capital-structure/">Capital Structure.

What the Company Announced

In its London Stock Exchange announcement, BioPharma Credit PLC — trading under the ticker BPCR LN and identified by LEI 213800AV55PYXAS7SY24 — confirmed that on 26 May 2026 it had purchased 150,000 of its ordinary shares through Investec Bank plc into treasury. The notice sets out that the lowest price per share was $0.95, the highest price per share was $0.95, the trading venue was the LSE, the aggregate Volume per date per trading venue was 150,000, and the weighted average price per day per trading venue was $0.95. Following the transaction, BPCR holds 251,739,289 of its ordinary shares in treasury and has 1,122,192,778 ordinary shares in issue excluding treasury. The total number of voting rights in the Company is therefore 1,122,192,778, and this is the figure shareholders may use as the denominator for calculations under the FCA’s Disclosure Guidance and Transparency Rules to determine whether they are required to notify their interest in, or a change to their interest in, the Company.

Details of the Own-Share Transaction

The detail in the announcement is unusually compact compared with many UK FTSE 100 buyback notices, reflecting the small size of the day’s purchase. The transaction was a single block of 150,000 ordinary shares all executed at $0.95, meaning the lowest price per share, the highest price per share and the weighted average price per day per trading venue were identical. The purchase consideration on the day implied by these figures is therefore in the region of $142,500 before any execution costs.

Key Transaction Data

  • Date of purchase: 26 May 2026
  • Number of ordinary shares purchased: 150,000
  • Lowest price per share: $0.95
  • Highest price per share: $0.95
  • Weighted average price per day per trading venue: $0.95
  • Trading venue: LSE
  • Aggregate volume per date per trading venue: 150,000
  • Treatment: Taken into treasury (not cancelled)
  • Broker: Investec Bank plc

Following the transaction, BioPharma Credit holds 251,739,289 of its ordinary shares in treasury and has 1,122,192,778 ordinary shares in issue (excluding treasury shares). The Company’s ordinary shares are denominated in US dollars at US $0.01 each, reflecting BPCR’s structure as a US-dollar focused life sciences debt vehicle listed on the London Stock Exchange.

Why Companies Buy Back Their Own Shares

A transaction in own shares is one of the principal tools available to listed companies and investment trusts to manage their share count and capital base. For an investment trust or closed-end fund like BPCR, Buybacks are particularly important because they can be used to help manage the discount at which the shares may trade relative to net asset value (NAV). When a fund repurchases shares at a price below NAV per share, the transaction is typically accretive to NAV per share for remaining shareholders. The decision to place the shares into treasury, rather than cancelling them, gives the board future flexibility to re-issue those shares should the Market Price move to a premium to NAV in the future. More broadly, Market Participants often view buybacks as a flexible mechanism to return capital and improve share-Supply dynamics, although the specific implications always depend on the fund’s mandate, Liquidity and net asset value.

What This May Signal to Investors

The BPCR announcement indicates that the board continues to be willing to deploy modest amounts of capital in its own ordinary shares when market conditions are appropriate. Because all 150,000 shares were purchased at the same price of $0.95, the trade was either executed in a single tightly priced block or at a price level the broker was able to source consistently in the market on the day. The transaction forms part of BPCR’s ongoing approach to managing its share register and treasury holdings, and the size of the day’s purchase is small relative to the total share count. Investors may watch whether further transaction in own shares notices follow in coming weeks and how the cumulative treasury holding evolves. As ever, the announcement is not a forecast of share price movements; market participants often interpret buybacks alongside other indicators such as NAV updates, portfolio activity and Dividend declarations.

Company Background

BioPharma Credit PLC is described in its own RNS notes as London’s only specialist debt investor to the life sciences industry. The Company joined the London Stock Exchange in March 2017 and has built a portfolio of investments primarily in debt Assets secured by royalties or other cash flows derived from the sales of approved life sciences products. BPCR’s stated objective is to provide long-term Shareholder returns, principally in the form of sustainable income distributions from exposure to the life sciences industry. The Company is identified by LEI 213800AV55PYXAS7SY24 and conducts shareholder communications through MUFG Corporate Governance Limited as company secretary. Public Relations enquiries are handled by Burson Buchanan, with Helen Tarbet, Jamie Hooper, Henry Wilson and Nick Croysdill listed as contacts in the announcement. The shares are denominated in US dollars, reflecting the underlying nature of the Company’s Loan and Royalty assets.

Market and Sector Context

BPCR sits in a niche corner of the London-listed investment trust universe focused on specialist life sciences debt. UK investment trusts more broadly have used buyback programmes as a tool to address discounts to NAV, particularly in sectors such as Private Equity, infrastructure, renewables and specialist credit, which have at various times traded at meaningful discounts to underlying asset valuations. For a US-dollar denominated trust like BioPharma Credit, dollar-funded buybacks executed in the London market also have implications for currency exposures and treasury management. The life sciences sector itself has been under varied scrutiny in recent years, with investor focus on royalty financing, biotech funding cycles and approvals shaping sentiment. Within that context, periodic transaction in own shares notices from BPCR are part of the routine flow of information for FTSE-listed investment trust investors monitoring both the buyback dynamic and the underlying portfolio.

Potential Impact on Shareholders

Because the 150,000 ordinary shares acquired on 26 May 2026 have been taken into treasury rather than cancelled, the number of ordinary shares in issue including treasury remains unchanged, while the number of ordinary shares in issue excluding treasury shares — and therefore the number of voting rights in the Company — has fallen by 150,000 to 1,122,192,778. As a result, remaining shareholders see a marginal increase in their proportionate economic interest and voting power within the Company. The decision to use treasury rather than outright cancellation also preserves optionality for the board to reissue those shares in the future, for example if market conditions change. The figure of 1,122,192,778 should now be used by shareholders as the denominator for calculations under the FCA’s Disclosure Guidance and Transparency Rules.

Risks and Points Investors Should Watch

BPCR’s buyback activity is just one input in a wider investment case that also depends on credit performance, royalty cash flows, exposure to specific biopharmaceutical assets, and the level of cash and undrawn commitments on the Balance Sheet. The announcement indicates a single day of activity rather than a multi-week programme, and investors should not extrapolate the day’s purchase into assumptions about future buyback volumes. Risks investors may watch include changes in interest rates that affect the value of the Company’s loan portfolio, idiosyncratic credit events at borrowers, regulatory or pricing developments affecting underlying life sciences products, and discount or premium fluctuations relative to NAV. Currency effects are also relevant given the US-dollar denomination of the ordinary shares. Investors should consider these factors alongside any further transaction in own shares notices when assessing the BPCR investor update flow.

What Happens Next

Investors will be looking out for any further RNS notices from BioPharma Credit covering additional own-share activity, NAV updates, portfolio commentary and dividend declarations. Should the Company continue to repurchase shares into treasury, the running treasury figure of 251,739,289 will rise further, while ordinary shares in issue excluding treasury and the total number of voting rights in the Company will fall accordingly. The next set of formal results and factsheets will offer more colour on portfolio performance and the contribution that buyback activity may be making to per-share Economics. Until then, the 26 May 2026 announcement stands as the most recent confirmed BPCR own-share data point.

Conclusion

The London Stock Exchange announcement issued by BioPharma Credit PLC at 18:15 on 26 May 2026 is a small but precise update for BPCR shareholders. By purchasing 150,000 ordinary shares at $0.95 through Investec Bank plc and taking them into treasury, the Company has marginally reduced its ordinary shares in issue excluding treasury to 1,122,192,778 while retaining the optionality to reissue. For investors in UK-listed specialist debt vehicles and life sciences investors more broadly, the disclosure adds to the picture of how BPCR is managing its share register alongside its core investment portfolio. As with any such notice, market participants will assess it in the context of NAV, distribution policy and the wider environment for life sciences debt rather than in isolation.